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1. Introduction 
Antibody molecules are bifunctional: the recogni- 
tion of foreign molecules by the Fab regions triggers 
the interaction of a variety of effector systems which 
are mediated through the Fc region, some 75A from 
the antigen recognition site. Activation of the effector 
systems culminates in the elimination of these foreign 
molecules. It has been more than 10 years since the 
positive identification of the antibody combining 
site by sequence analysis [1,2] followed by chemical 
modification and peptide mapping studies [3]. Con- 
currently with the elucidation of the molecular 
sequence [4] and three-dimensional structure of the 
immunoglobulin molecule [S-7] there have been 
continual efforts to locate the site of the many 
immunoglobulin effector functions. The best charac- 
terized of these effector systems i  the classical com- 
plement system [8,9]. Porter and colleagues unam- 
biguously identified the Cr2 domain as the domain 
which binds Cl q, the first subcomponent of comple- 
ment [lo]. Efforts to elucidate the molecular details 
of the site triggering the cqmplement effector system 
by: (1)inhibitorypolypeptides [ll-14];(2)chemical 
modifications of antibodies [ 12,15,16]; (3) dialysis 
of IgG sequences [ 171 have proved ambiguous and 
controversial. In [ 181 we proposed a receptor site on 
the Cy2 domain of IgG for the Clq molecule based 
on 3 lines of analysis: (1) conservation of sequence 
and accessibility of amino acid residues to solvent; 
(2) inhibitors of the Cl q-IgG interaction; (3) chem- 
ical modification of amino acid residues on IgG and 
Clq. The proposed site was on the two C-terminal 
p-strands of the Cy2 domain which contains everal 
highly conserved and accessible Glu, Lys, Thr and Ser 
residues (fig.4b). This postulate was consistent with 
the results of inhibitor studies and chemical modifi- 
cations which suggested that: (1) Clq-IgG interac- 
tions are largely ionic in nature; (2) lysine, glutamic 
acid and/or aspartic acid, but not arginine and tryp- 
tophan residues are in the Cl q receptor site on the 
Cy2 domain. Here, we have chemically modified and 
mapped alysine residue which confirms the location 
of the postulated Cl q receptor site. This is the first 
time direct chemical studies have led to positive 
identification of the site of any immunoglobulin 
effector function. 
2. Materials and methods 
2.1. Modification of IgG 
Immune rabbit IgG (anti-ovalbumin) was prepared 
asin [21] thenmodified with [ 1-14C]aceticanhydride 
which reacts with lysine residues [ 19,201. The condi- 
tions of modification, acetate buffer at pH 5 .O and 
O”C, are extremely mild and do not lead to protein 
denaturation. 
Comparison of precipitin curves and circular 
dichroism spectra for the modified and control IgG 
were also as in [21]. 
2.2. Clq -IgG aggregates binding assay 
Both the modified and control rabbit anti-ovalbumin 
IgG were formed into antigen-antibody aggregates at 
the same equivalence as determined from precipitin 
curves. The binding of 12SI-labelled Clq to these 
aggregates was measured by a modification [21] of 
the method in [33]. 
2.3. HPLC separation 
This was performed on a Bondapak C 18 column in 
O.l%TFA/solvent X (methanol:acetonitrile:2-propanol) 
(1 :l: 1, by vol.) or in 0.1% ammonium bicarbonate/ 
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acetonitrile as in [34] using a Water Associates HPLC 
system. 
2.4. Amino acid sequence determination 
These were carried out on a Beckman 890C 
sequencer as detailed in [34]. 
3. Results 
The overall strategy of correlating the functional 
loss of Clq binding activity with identification of the 
modified lysine(s) is shown in fig.1. We had shown 
that modification of lysines inhibits Cl q-IgG com- 
plex formation [ 2 11. The modification was minimal 
to ensure that there was: (1) no alteration in either 
conformational integrity or the antigen binding 
capacity of the IgG molecules measured by CD spectra 
and precipitin curves; (2) specific labelling of few 
lysine residues. The specific activity of the modifying 
acetate groups indicated that there was 1.2 + 0.2 
modified residues/whole IgG. After modification the 
functional dissociation constant of IgG and Clq was 
significantly altered (fig.2) in comparison with 
unmodified IgG immune aggregates from the same 
rabbit. There was no change in relative capacity of 
IgG for Cl q. The functional dissociation constant 
for the modified aggregates is 2.3 X 1 O-* M-r and for 
the control aggregates is 1 .O X lo-’ M-l. These data 
Mpg Clqfreehl) 
Fig.2. Clq binding to acetic anhydride modified IgG aggre- 
gates. The acetic anhydride reaction with lysine residues is 
shown. The inverse of the amount of Clq bound vs the 
inverse of the Clq free is plotted for the control aggregates 
(0) and the acetic anhydride modified aggregates (0). The 
lines computed fit to the experimental points using a 
non-linear least squares program. The values of Kd (and the 
standard error) so obtained are 1.0 X lo-’ M-l (0.17) and 
2.3 X 10e8 M-’ (0.3) for the control and modified aggre- 
gates, respectively. The corresponding relative values of the 
capacities are 1 .O (0.06) and 1.03 (0.07). 
Flow Plan of Identification of Modified Lysines on Rabbit 
(1) [14C] Acetic Anhydride Modification of Rabbit IgG 
W 
(21 Test of Conformational Integrity 
(al Precipitin Curve 
lb) Circular Dichroism Spectra 
(3) Test of Clq Binding - Fig. 2. 
(4) Reduction and Alkylation of IgG. 
(5) Separation of Heavy and Light Chains. 
(6) CNBr Cleavage of Heavy Chain. 
(7) Fractionation of Radiolabelled CNBr Fragments - 
Fig. 3a. 
(8) Pepsin Digest of Radiolabelled CNBr Fragments. 
(9) Isolation and Purification of Peptic Fragments- 
Fig.3b. 
(10) Sequence Determination of Peptic Fragments- 
Fig. 40. 
Fig.1. 
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agree with our results for acetic anhydride modified 
IgC where 2.2 + 0.3 modified lysine residues on IgG 
changed the binding affinity 29-fold [21]. This is a 
significant change in binding affinity since modifica- 
tions of arginine and tryptophan residues have no 
effect on Clq binding affinity for IgG. 
‘Ihe modified IgG was then subjected to peptide 
mapping to identify the modified lysine residue(s) 
as in fig.1. After the separation of heavy and light 
chains [22] it was determined by the specific activity 
that -20% of the radioactive acetate groups were in 
the light chain. Paper electrophoresis in SDS of the 
heavy chain CNBr digest [23] indicated that all the 
radioactive acetate groups were in one peak. Frac- 
tionation of the digest using Ultrogel Aca 54 in 30% 
(v/v) HCOOH resolved 2 peaks, One of these con- 
tains 25% of the recovered radioactivity and from 
PAGE analysis probably corresponds to aggregated 
material, the Cl peptide (up to residue 252), and 
products of partial cleavage at methionine residues 
[37]. The main radioactive peak (75%) corresponds 
to the C3 peptide (residues 252-350) and a large 
peptide [37]. The HPLC purification of this main 
radioactive peak similarly indicated that the radioac- 
tive acetate groups were in one fragment (fig3a). 
The whole of the main radioactive peak of CNBr 
fragments was digested by pepsin [24] and then puri- 
fied on a G-25 gel filtration column. The radioactive 
peak of the gel filtration effluent was concentrated 
and then further purified on HPLC (fig3b). The 2 
radioactive peaks on the final HPLC column, peptide 
A (the minor peak) and peptide B (the major peak), 
were then sequenced. Peptide A was a shorter sub- 
fragment of peptide B, with the identical lysine resi- 
due modified. The 2 fractions containing peptides A 
and B represent 8% and 44% of the radioactivity 
applied to the column and they constitute 70% of 
the total recovered radioactivity. 
The sequence determination of peptide B gave a 
sequence in the Cy2 domain between residues 319 
and 332 (figAa). The peptide A sequence was between 
residues 319 and 322. In the peptide B sequence 
there are 3 lysine residues: Lys (320), Lys (322) and 
Lys (326). Only Lys (322) was modified. The quanti- 
tative yield of Lys (322) in the sequence determina- 
tion revealed that only 8% was modified. This 
shows that the HPLC purification does not prefer- 
entially distinguish the modified and unmodified 
peptides containing this lysine. The specific activity 
of this acetyl ysine residue was 8 X lo3 dpm/nm 
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compared to a specific activity of -2.5 X 1 O3 dpm/nm 
for the entire heavy chain. Neither Lys (320) nor Lys 
(326) were modified to any detectable xtent, <l% 
of Lys (322). 
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Fig.3. HPLC on CNBr fragments and peptic fragments. The 
chromatography was performed at 1 ml/min flow rate. In 
(3a) the CNBr fragments of the H-chain were chromatographed 
using the system methanol:acetonitrile:2-propanol(1 :l :1, by 
vol). In (3b) the peptic fragments of the main radioactive 
peak (75%) of CNBr products was applied to the column 
using the 0.1% ammonium bicarbonate acetonitrile system. 
In both (3a) and (3b) time is in minutes after the beginning 
of the gradient. The absorbance was monitored at 206 nm. 
The radioactivity measurements in the histogram were per- 
formed on 500 1 samples from (a) and 200 1 samples from @) 
in 0.5% 2,5diphenyloxazole in dioxan scintillant. From the 
second HPLC run (3b) peptide A and peptide B were isolated 
and sequenced. 
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Fig.4. The sequence and conformation of the Clq binding 
site on the Cr2 domain of IgC. (a) The primary sequence of 
peptide B isolated from the peptic fragments using HPLC 
(fig.3b). The radiolabeBed acetyl lysine is indicated (**). 
(b) The Cr2 domain containing peptide B (residues 319- 
322) and the remaining portions of the fy2 and fy3 p-strands 
from rabbit IgG are shown. This view is derived from the 
crystallographic data in [ 71 for human Fc using the amino 
acid side chains for rabbit IgG. 
4. Discussion 
The specific modification of Lys (322) with the 
loss of Cl q binding affinity clearly demonstrates that 
this lysine is in or near to the Cl q receptor site on 
IgG. This verifies our original postulate that residues 
in the 2 C-terminal o-pleated sheets of the C-y2 
domain, which contains Lys (322) (fig_4b), are the 
Clq receptor site. 
The modification of Lys (322) does not delineate 
the extent of the Clq receptor site on IgG. However, 
several other residues of the fy2 and fy3 p-strands 
(nomenclature from [25]) are probably necessary for 
a Cl q receptor site on IgG. A likely set of conserved, 
accessible r sidues consistent with our chemical 
modification studies and continuous with Lys (322) 
that could serve as a Cl q receptor site are: Glu (3 18) 
Lys (320), Lys (322), Glu (333), Thr (335) and Ser 
(337). These are all part of the 2 parallel p-sheets, 
fy2 and fy3. The b6 bend which links these 2 parallel 
o-sheets i probably not part of the Cl q binding site 
since it is involved in Cyl -C-r2 domain interactions 
[7] @igAb). 
We had demonstrated that Cl q-IgG complex for- 
mation is largely the result of ionic interactions and is 
not driven wholly by shielding of hydrophobic resi- 
dues as proposed [26]. The Clq receptor site identi- 
fied here is consistent with this conclusion. All of 
these residues can participate in ion bridges either 
between oppositely charged residues or between 
similarly charged residues using bridging water or 
chloride molecules [27]. Since the binding between 
Cl q and monomer IgG is not very tight, with a disso- 
ciation constant of lo4 M-l, it is conceivable that 
several ionic bridges may comprise the total binding 
energy of the Cl q-IgG interaction. Consistent with 
this idea, modification of the single Lys (322) with a 
loss of its charge (fig.2) causes amoderate decrease 
in the binding affinity of C 1 q for IgG but does not 
eliminate binding, which would be reflected in a 
decrease in the capacity of IgG for Cl q. 
The Clq-IgG binding described here contrasts 
with that for antigen-antibody systems. The antigen 
binding site on antibodies involves a cleft or a groove 
constructed from 2 distinct chains into which the 
antigen fits. The antigen binding to antibodies i  a 
shape problem in which the different antigens alter 
their position within the combining site so as to 
maximize Van der Waal’s and hydrophobic interac- 
tions [28,29]. The Clq binding to antibodies on the 
other hand is a surface matching problem. The Cl q 
receptor site on IgG is a p-strand array of charged 
and polar residues and recognition probably requires 
a complementary array of charged and polar residues 
on the Cl q molecule. This type of surface contact 
may be the main type of interaction in the recogni- 
tion between large proteins [30,31]. Cytochrome c
peroxidase-cytochrome c recognition may occur by 
a matching of charged arrays containing lysine and 
aspartic acid residues [32]. The other immunoglo- 
bulin effector functions may be mediated by a 
similar surface-charged array to that for Clq binding 
on IgG. Localization of the sites of these effector 
functions on the immunoglobulin Fc utilizing an 
approach similar to that outlined in [ 181 and here, 
by our identification of the Clq receptor site, should 
test this postulate. 
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